Approximately 60% of DLBCL patients are in the clear after standard first-line therapy…

…while the other 40% get lost in the forest. Could these outcomes be improved?

First line remains our best opportunity for cure in DLBCL1—and reassessing our first-line approach could improve outcomes for even more patients.

Approximately 60% of DLBCL patients are in the clear after standard first-line therapy…

…while the other 40% get lost in the forest. Could these outcomes be improved?

First line remains our best opportunity for cure in DLBCL1—and reassessing our first-line approach could improve outcomes for even more patients.

Up to 4 out of 10 patients will relapse or be refractory to first-line therapy in DLBCL1,2

While approximately 60% of patients with DLBCL can be cured with first-line standard of care, unfortunately the remaining 40% of patients will relapse or be refractory to first-line therapy.1,2

 

Most relapses occur within 24 months of starting treatment; however, patients who remain progression-free 24 months post initiation of first-line therapy have excellent outcomes—with survival that is clinically indistinguishable from the general population.2,3

4 out of 10@2x.png
Successful Outcome@2x.png

First line is the best opportunity to achieve a successful outcome in DLBCL1,4

The majority of patients with relapsed-refractory disease have poor outcomes.4-6

 

Patients who need second and subsequent lines of therapy experience poor prognoses—and with disease progression, also experience increased risk of side effects and greater burden on the healthcare system.7,8

Substantial unmet medical need remains in the first-line setting of DLBCL

In the more than 20 years since R-CHOP was established as the first-line standard of care, no regimen has demonstrated a meaningful improvement in outcomes over R-CHOP in a phase III trial.4,9,10

 

Priority should be placed on the development of treatment strategies that can further reduce the risk of disease progression in the first-line setting and therefore increase the likelihood of curative outcomes.1,5

Unmet Medical Need@2x.png

Expert Perspectives

What does a DLBCL diagnosis mean for patients?

Improving outcomes in diffuse large B-cell Lymphoma

What does it mean to you as a physician to see a DLBCL patient relapse?

Clinical and patient advocates perspectives: How can we improve outcomes for patients with DLBCL?

Expert Perspectives

Video 1.png

What does a DLBCL diagnosis mean for patients? 0:45

Video 2.png

Improving outcomes in diffuse large B-cell Lymphoma 3:44

Video 3.png

What does it mean to you as a physician to see a DLBCL patient relapse? 0:41

Video 4.png

Clinical and patient advocates perspectives: How can we improve outcomes for patients with DLBCL? 8:14

“Focusing on the front-line space to improve upon outcomes and improve cure rates is absolutely vital”

- Dr.Graham Collins (Hematologist, UK)

“The stakes really go up once patients have that relapse or progression…and it does become a much more threatening situation”

- Dr.Laurie Sehn (Hematologist, Canada)

DLBCL=diffuse large B-cell lymphoma.

 

References:

  1. 1. Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125(1):22-32.
  2. 2. Maurer MJ, Ghesquières H, Jais JP, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32(10):1066-1073. 
  3. 3. Maurer MJ, Habermann TM, Shi Q, et al. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Ann Oncol. 2018;29:1822-1827.
  4. 4. Nowakowski GS. Recently approved drugs herald a new era in therapy for diffuse large B-cell lymphoma. Clin Adv Hematol Oncol. 2021;19(5):284-287.
  5. 5. Karlin L, Coiffier B. Improving survival and preventing recurrence of diffuse large B-cell lymphoma in younger patients: current strategies and future directions. Onco Targets Ther. 2013;6:289-296. .
  6. 6. Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842-858.
  7. 7. Elstrom RL, Martin P, Ostrow K, et al. Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clin Lymphoma Myeloma Leuk. 2010;10(3):192-196. 
  8. 8. Purdum A, Tieu R, Reddy SR, Broder MS. Direct costs associated with relapsed diffuse large B-cell lymphoma therapies. Oncologist. 2019;24(9):1229-1236.
  9. 9. Shi Q, Schmitz N, Ou FS, et al. Progression-free survival as a surrogate end point for overall survival in first-line diffuse large B-cell lymphoma: an individual patient–level analysis of multiple randomized trials (SEAL). J Clin Oncol. 2018;36(25):2593-2602.
  10. 10. Iacoboni G, et al. Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review. Ann Oncol. 2018;29(5):1120-1129.